Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

J Infect. 2024 Mar;88(3):106120. doi: 10.1016/j.jinf.2024.106120. Epub 2024 Feb 16.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing*
  • COVID-19*
  • Clinical Trials, Phase III as Topic
  • Drug Combinations
  • Humans
  • Randomized Controlled Trials as Topic

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • cilgavimab
  • cilgavimab and tixagevimab drug combination
  • Drug Combinations
  • tixagevimab